Area:
Molecular Biology, Oncology, Pathology
We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Rebecca Bascom is the likely recipient of the following grants.
| Years |
Recipients |
Code |
Title / Keywords |
Matching
score |
| 1989 — 1993 |
Bascom, Rebecca |
R29Activity Code Description:
Undocumented code - click on the grant title for more information. |
Respiratory Sensitivity to Environmental Tobacco Smoke @ University of Maryland Baltimore
The overall objective of this proposal is an increased understanding of respiratory sensitivity to environmental tobacco smoke (ETS). These proposed studies represent the logical outgrowth of our preliminary studies which showed that: 1) In a survey of healthy nonsmokers, a history of rhinitis symptoms after exposure to environmental tobacco smoke was reported by 40% of subjects. 2) Controlled challenge with sidestream tobacco smoke (STS) in an environmental chamber results in increased rhinitis symptoms and an increase in posterior nasal resistance in historically ETS sensitive subjects as compared to historically ETS-nonsensitive objects. 3) ETS sensitive subjects are more likely to be atopic by skin prick tests. 4) There is no increase in nasal lavage histamine following STS exposure; this suggests that mast cell activation is not the basis for ETS sensitivity. Studies in this proposal are aimed at testing the hypothesis that ETS sensitivity in humans represents a neurally mediated increased inflammatory response to the vapor phase component of STS. Other investigators have shown that a response to cigarette smoke in animals is mediated by C-fiber afferent neuron stimulation by the vapor phase component of smoke. We will first characterize the symptomatic, physiologic and inflammatory response to STS over a dose range found in indoor environments. Next, we will determine whether ETS-sensitive subjects are hyper-responsive to the organic vapor component of STS. We will explore the mechanism of ETS sensitivity by attempting to block the response to STS pharmacologically. We will then explore lower respiratory sensitivity to ETS, by determining whether STS causes decrements in lung function or increased reactivity under conditions of moderate exercise in ETS sensitive subjects. Finally, we will investigate the interaction between allergic illness and ETS. We will test the hypothesis that antigen challenge will increase the responsiveness to subsequent STS exposure. This latter hypothesis is based on clinical, anecdotal evidence and on animal causes prolonged depolarization of neurons. It is our opinion that an increased understanding of sensitivity to environmental tobacco smoke will result in a better understanding of non-allergic rhinitis and aid in the development of rational control and therapeutic measures for this prevalent condition.
|
0.934 |
| 1999 — 2002 |
Bascom, Rebecca |
M01Activity Code Description:
An award made to an institution solely for the support of a General Clinical Research Center where scientists conduct studies on a wide range of human diseases using the full spectrum of the biomedical sciences. Costs underwritten by these grants include those for renovation, for operational expenses such as staff salaries, equipment, and supplies, and for hospitalization. A General Clinical Research Center is a discrete unit of research beds separated from the general care wards. |
Pharmacokinetics of Grepafloxacin &Ciprofloxacin in Lung @ Pennsylvania State Univ Hershey Med Ctr
The purpose of this study is to determine the concentration of the antibiotic Grepafloxacin (Raxar) or Ciprofloxacin (Cipro) in the lung after taking a single dose. Both drugs are used for treating lung infections such as pneumonia and acute exacerbations of chronic bronchitis caused by bacteria that are resistant to many antibiotics. The greater the amount of antibiotic that is deposited at the site of the infection, the faster the bacteria is eliminated and the course of treatment is shorter.
|
0.966 |